Your
monthly newsletter from the
"better way to access market intelligence" people at medintellibase.com |
|||||||||||||||||
Table
of
Contents
|
|||||||||||||||||
| 1) Science, Innovation,
Synergy - SIS 2007 Conference in Seattle A Course in Cardiac, Vascular, and Neurovascular Therapeutics & Emerging Technology Symposium Look for several special MIB NewsTips issues over the next few weeks describing the upcoming SIS 2007 conference, August 1-4. This combined comprehensive course and emerging technology symposium is directed by opinion leaders in vascular medicine and is intended for those medical professionals and industry experts with a clinical or technical interest in interventional medicine.
Return to Top |
|||||||||||||||||
| 2) "SONOMA" now joins
"CABERNET" Boston Scientific Corporation has announced the "Post-Market Approval Study of the NextStent Carotid Stent System and the FilterWire EZ Embolic Protection System." This "SONOMA" Post-Market Approval study, a multi-center, U.S. surveillance registry, enrolled the first of 1,650 patients on May 31, 2007. One hundred sites are planned with scheduled closure of the registry in September 2009. The study will confirm the safety of the NexStent Carotid Stent System and FilterWire EZ Embolic Protection System used in daily clinical practice for the approved indications. To review a detailed overview of the study as depicted below in a SMArt Trial Summary at MedIntelliBase.com, go to "SONOMA" study.  Subbarao Myla, M.D., Medical Director of Cardiovascular Research and Vascular Intervention, Hoag Heart and Vascular Institute, Hoag Memorial Hospital Presbyterian Newport Beach, CA, the principal investigator for SONOMA, enrolled the first patient. In the BSCI press release issued June 1, Dr. Myla was quoted as saying "We are hopeful that the unique design and other features of the NexStent Carotid Stent and FilterWire EZ Embolic Protection System will facilitate a high procedure success rate and relatively low risk of major disabling stroke or death in a cohort of patients with symptomatic and asymptomatic carotid artery stenosis that are at high risk for surgery." A 500-patient cohort will be included to allow an independent core lab to review analyze patient success based on routine duplex ultrasound evaluations. The "CABERNET" Multi-center Trial ["Carotid Artery Revascularization Using the Boston Scientific EPI FilterWiRe EX and the Endotex NExStenT"] results supported the FDA’s October 27, 2006 PMA approval of both devices. Published September 23, 2005, the CABERNET trail was designed for 600 patients and concluded with 454 patients enrolled, with 438 showing a stroke rate of 1.3 percent, and a combined stroke, death, and MI rate of 3.9 percent. To review the final trial results in a SMArt Trial Summary at MedIntelliBase.com, go to "CABERNET". These SMArt Trial summaries and over 800 others are available to subscribers to MedIntelliBase MarketTracks databases. Contact us to access specific and/or customized clinical trial and registry summaries of interest to you. Interested in keeping up to date on this issue? Is there another area of interest where you need current, timely clinical research or technology development information? Click here to learn more about our MIB Alerts - A Better Way...to stay up to date. Return to Top |
|||||||||||||||||
| 3)
MedIntelliBase SMArt Stats - Custom U.S. Healthcare Procedure Data Announcing a new service! The Next Phase Publishing is pleased and excited to announce its newest offering, MIB SMArt Stats. MIB SMArt Stats offer users customized U.S. procedure data based on the American Medical Association's Current Procedural Technology (CPT) and International Classification of Diseases (ICD-9) coding systems. Utilizing data sets available from U.S. governmental sources including the Centers for Medicare & Medicaid Services (CMS) and the Agency for Healthcare Research and Quality (AHRQ), procedure volumes and associated charge data are now easy and quick for you to access. For any and all CPT codes that you need by year, MIB SMArt Stats reports can take you to the state and municipal area levels of granularity. Up to 20 additional, directly associated data fields are available providing details on carriers and physicians for each procedure. Until now, the process has been complex. If you venture into this alone it can consume hundreds of hours of your team's valuable time and innumerable resources to generate accurate and usable data tables and reports. MIB SMArt Stats changes all of this and provides all data for you, quickly, easily, and accurately. If you have any questions about MIB SMArt Stats or would like further information about our customized service, go to MIB SMArt Stats Info Request form or contact us directly. Is there another area of interest where you need current, timely clinical research or technology development information? Click here to learn more about our MIB Alerts - A Better Way...to stay up to date. Return to Top |
|||||||||||||||||
4) Link
of the Month
|
|||||||||||||||||
5) Fun Fact of the Month
|
|||||||||||||||||
| 6)
MedIntelliBase Custom Email
Alerts now give you A
Better Way Coming in July - MedIntelliBase Custom Email Alerts with newly updated capabilities including Full-Featured Search. Search any or all of these databases customized to your area of interest:
 Click the image above to view
sample MIB Custom Email Alert formats - a "FullView" Alert, or one of
the
"QuickView" formats --> Lean Alert or UltraLean Alert.
A Better WayDoes this "quest for Market Intelligence" sound familiar?
MIB Alerts MedIntelliBase
Custom Email Alerts are highly
flexible,
customized intelligent search filters powered by "Human
Intelligence™" that give you convenient, timely,
and tightly focused updates on new developments in your industry
segment. MIB
Alerts are especially suitable for busy Marketing,
Business Development, and General Management executives in medical
device and biotechnology companies.
Convenient and Timely
Easy
to use
Customized
and Tightly Focused
A few examples of thousands of possibilities for Alert topics:You get much greater value from customizable MIB Alerts than from standard market reports and search engines. You choose the exact depth and breadth of intelligence required, realizing the greatest value for your market intelligence money. Interested? Want to know more? Want a trial? Contact us for:
|
|||||||||||||||||
|
|||||||||||||||||
| 8) More
Information Available at www.MedIntelliBase.com You can find more in-depth information about MedIntelliBase Custom Email Alerts - visit the website at www.MedIntelliBase.com or request more information on the site. MedIntelliBase MarketTracks and Alerts will help you find the critical intelligence you need to make informed product development and business investment decisions. Contact MedIntelliBase directly... Return to Top |
|||||||||||||||||
FYI:
Editor: Vicky Hunsicker Sanko The Next Phase Publishing** Market Research Analyst: Jordan Zornes The Next Phase Publishing** Phone - 425/894-4147 www.MedIntelliBase.com Toll Free - 800/390-2756 Fax - 866/381-6119 ** A division of Next Phase® Consultancy, Inc. © The Next Phase® Consultancy, Inc. 2007. All rights reserved. Return to Top |
